Asset Management One Co. Ltd. Has $10.53 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Asset Management One Co. Ltd. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 58.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 145,028 shares of the medical equipment provider's stock after buying an additional 53,762 shares during the quarter. Asset Management One Co. Ltd. owned about 0.06% of Hologic worth $10,529,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. State Street Corp increased its position in Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock worth $847,944,000 after buying an additional 81,057 shares during the last quarter. FMR LLC increased its position in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after buying an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock worth $208,051,000 after buying an additional 18,774 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock worth $200,952,000 after buying an additional 195,285 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after buying an additional 544,889 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Mizuho lowered their price target on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Raymond James reaffirmed an "outperform" rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. BNP Paribas raised Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Finally, Stephens reaffirmed an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.77.

Hologic Price Performance

HOLX traded up $0.12 during midday trading on Thursday, reaching $64.32. 1,953,696 shares of the company's stock were exchanged, compared to its average volume of 2,481,100. The firm has a market capitalization of $14.43 billion, a price-to-earnings ratio of 20.29, a price-to-earnings-growth ratio of 2.12 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a one year low of $62.69 and a one year high of $84.67. The business has a 50-day simple moving average of $70.31 and a two-hundred day simple moving average of $76.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.88% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.